Value of pharmaceuticals: Ensuring the future of research and development

Journal of the American Pharmacists Association

Volumn 46, Issue 4, 2006, Pages 511-516

  Serajuddin, Hamida K ^a   Serajuddin, Abu T M ^a,b  

^a Arnold and Marie Schwartz College of Pharmacy ^*  (United States)

^b Arnold and Marie Schwartz College of Pharmacy   (United States)

Author keywords

Medications; Patents; Pharmaceutical industry; Pharmaceutical marketing; Research and development

Indexed keywords

DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; PHARMACEUTICAL CARE; REVIEW; ARTICLE; DRUG APPROVAL; ECONOMICS; LEGAL ASPECT; MEDICAL RESEARCH; ORGANIZATION AND MANAGEMENT; PATENT; UNITED STATES;

BIOMEDICAL RESEARCH; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; PATENTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33748556893     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434506778073682     Document Type: Article

References (19)

1. Angell M. The truth about drug companies. New York: Random House; 2004.
2. Kessirer JP. On the take. New York: Oxford University Press; 2005.
3. DiMasi JA, Paquette C. The economics of follow-on drug research and development-trends in entry rates and the timing of development. Pharmacoeconomics. 2004;22(suppl 2):1-14.
4. Centers for Medicare and Medicaid Services, Research, statistics, data & systems; Statistics, trends & reports. National health care expenditure data. Medicare and Medicaid statistical supplement, 2005 ed., table 4a. Accessed at www.cms.hhs.gov/medicaremedicaidstatsupp/, April 19, 2006.
5. Pharmaceutical industry profile 2006. Pharmaceutical Research and Manufacturers of America: Washington, D.C.; 2006. Accessed at www.phrma.org, April 19, 2006.
6. Hussar DA. New drugs of 1996. J Am Pharm Assoc. 1997;37:192-95.
7. Hussar DA. New drugs of 1997. J Am Pharm Assoc. 1998;38:155-98.
8. Hussar DA. New drugs of 1998. J Am Pharm Assoc. 1999;39:151-206.
9. Hussar DA. New drugs of 1999. J Am Pharm Assoc. 2000;40:181-231.
10. Hussar DA. New drugs of 2000. J Am Pharm Assoc. 2001;41:229-72.
11. Hussar DA. New drugs of 2001. J Am Pharm Assoc. 2002;42:227-66.
12. Hussar DA. New drugs of 2002. J Am Pharm Assoc. 2003;43:207-48.
13. Hussar DA. New drugs of 2003. J Am Pharm Assoc. 2004;44:168-210.
14. Hussar DA. New drugs of 2004. J Am Pharm Assoc. 2005;45:185-217.
15. ASHP news: new drug and biologic product approvals 2005 (January 31, 2005), American Society of Health-System Pharmacists. Accessed at www.ashp.org/news/, April 19, 2006.
16. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-85.
17. Grabowski H. Are the economics of pharmaceutical research and development changing? Productivity, patents and political pressures. Pharmacoeconomics. 2004;22(suppl 2):15-24.
18. The NIH Almanac-Appropriations. National Institutes of Health: Bethesda, Md.; 2006. Accessed at www.nih.gov/about/almanac/ appropriations/part2.htm, April 19, 2006.
19. Barton JH, Emanuel EJ. The patents-based pharmaceutical development process. Rationale, problems, and potential reforms. JAMA. 2005;294:2075-82.